ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1509

Immunogenicity, Adalimumab Levels and Clinical Response In Ankylosing Spondylitis Patients During 24 Weeks Of Follow-Up

Eva L. Kneepkens1, James C. Wei2, Michael T. Nurmohamed3,4, Kai-Jieh Yeo5, CY Chen6, Irene E. van der Horst-Bruinsma1,7, Desiree van der Kleij8, Theo Rispens9, Gertjan Wolbink3,9 and Charlotte L. M. Krieckaert3, 1Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2Allergy/Immunology/Rheumatolog, Chung Shan Med Univ Hospital, Taichung, Taiwan, 3Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 4Rheumatology, VU University medical centre, Amsterdam, Netherlands, 5Division of Allergy, Immunology and Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, 6Chung Shan Med Univ Hospital, Taichung, Taiwan, 7Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 8Sanquin Diagnostic Services, Amsterdam, Netherlands, 9Sanquin Research, Amsterdam, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: adalimumab and ankylosing spondylitis (AS), Personalized Medicine

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Immunogenicity influences adalimumab levels and therefore clinical response in patients with rheumatic diseases.

Objectives: To study the relation between clinical response, adalimumab levels and anti-drug antibodies (ADA) in ankylosing spondylitis (AS) patients.

Methods: Prospective observational cohort study of 115 consecutive AS patients treated with adalimumab in the Netherlands (n=85) and Taiwan (n=30), monitored during a maximum of 24 weeks. Adalimumab levels and ADA titres were determined retrospectively using an enzyme linked immunosorbent assay (ELISA) and an Antigen Binding Test (ABT), respectively, designed by Sanquin Research, Amsterdam. Response to adalimumab treatment was defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) response (50% improvement or an absolute improvement of 2 points on a BASDAI, scale 0-10) and disease activity was measured using the AS Disease Activity Score, including CRP (ASDAS).

Results: Of 115 patients 78 (67.8%) were male and 95 (82.6%) were HLA-B27 positive. At baseline median BASDAI (IQR) was 6.4 (4.5-7.6) and mean ASDAS (SD) was 3.5 (1.0). After 24 weeks of follow-up 49 (42.6%) patients were BASDAI responders (last observation carried forward). Mean ASDAS (SD) for responders was 1.5 (1.0) vs. 2.6 (1.0) for non-responders (p<0.001). Nine patients dropped out: 8 patients due to treatment failure or adverse events and 1 due to loss of follow-up. Thirty-one (27.0%) patients had detectable ADA. Median ESR levels (mm/hour) were significantly different between patients with or without ADA (respectively, 35.5(13.0-52.5) vs.19.0 (7.0-34.0), p=0.008). After 24 weeks, median adalimumab level (mg/L) (IQR) was significantly higher for ADA negative than for ADA positive patients (12,7 (8.2-18.0) vs. 1.2 (0.0-2.0),  p<0.001). At 24 weeks the percentage of detectable ADA was higher in patients from Taiwan 12 (40.0%) vs. Dutch patients, 19 (22.4%) (p=0.06). General estimate equation analysis demonstrated a significant association between adalimumab levels and ASDAS (p=0.02; RC -1.1; 95% CI -2.0 to -0.2). For BASDAI response no significant association with adalimumab levels was found. Eleven (9.6%) patients had no detectable adalimumab levels and high detectable ADA titres (>100 AU/mL). In these patients CRP and ESR remained elevated, although BASDAI decreased during 24 weeks of follow-up.

Conclusion: Adalimumab levels are related to clinical response in AS patients and are influenced by ADA detectable with an ABT. Therefore therapeutic drug monitoring should be investigated further as a possible tool to optimise treatment. 

Fig. 1. Median CRP levels (mg/L) for AS patients divided in 3 groups: no detectable ADA titres with normal drug levels (> 5 mg/L); intermediate detectable ADA titres with low drug levels (< 5 mg/L) and high detectable ADA titres with low drug levels (< 5 mg/L) during 24 weeks of follow-up.


Disclosure:

E. L. Kneepkens,
None;

J. C. Wei,
None;

M. T. Nurmohamed,

Abbott Immunology Pharmaceuticals,

2,

Roche Pharmaceuticals,

2,

Pfizer Inc,

2,

Abbott Immunology Pharmaceuticals,

5,

Roche Pharmaceuticals,

5,

Pfizer Inc,

5,

MSD,

5,

UCB,

5,

SOBI,

5,

BMS,

5,

Abbott Immunology Pharmaceuticals,

8,

Roche Pharmaceuticals,

8,

Pfizer Inc,

8;

K. J. Yeo,
None;

C. Chen,
None;

I. E. van der Horst-Bruinsma,
None;

D. van der Kleij,
None;

T. Rispens,
None;

G. Wolbink,

Pfizer Inc,

2,

Pfizer Inc,

8,

Amgen,

8;

C. L. M. Krieckaert,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunogenicity-adalimumab-levels-and-clinical-response-in-ankylosing-spondylitis-patients-during-24-weeks-of-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology